Novartis announced that Jonathan Symonds, currently managing director, investment banking at Goldman Sachs, will join the company as deputy CFO and designate Sept. 1, 2009. Raymund Breu, currently Novartis’s CFO, is planning to retire from the company March 31, 2010. Symonds has previously worked as CFO at AstraZeneca, and was also a partner at KPMG.
Elan announced the appointment of Richard Pilnik to non-executive director. He will join the company’s board on June 1. Pilnik was formerly group vice president and chief marketing officer at Eli Lilly, where he was responsible for commercial strategy, market research and medical marketing.
